Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What is a Nervous System?01:25

What is a Nervous System?

105.4K
Overview
105.4K
The Parasympathetic Nervous System01:14

The Parasympathetic Nervous System

116.0K
Overview
116.0K
The Sympathetic Nervous System01:25

The Sympathetic Nervous System

104.1K
Overview
104.1K
The Central Dogma01:25

The Central Dogma

140.1K
Overview
140.1K
The Central Dogma01:20

The Central Dogma

34.1K
The central dogma explains the flow of genetic information from DNA nucleotides to the amino acid sequence of proteins.
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
34.1K
Nervous System01:21

Nervous System

3.6K
The nervous system coordinates body functions through its complex network of nerve cells, enabling sensation and movement. It is divided into two primary parts: the central nervous system (CNS) and the peripheral nervous system (PNS). The CNS is composed of the brain and the spinal cord. The brain acts as the body's control center, processing sensory information and coordinating responses. The spinal cord functions as a major signaling pathway for the brain and the rest of the body.
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.

Future oncology (London, England)·2026
Same author

Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairment.

Neuro-oncology practice·2026
Same author

Noninvasive Identification of Isocitrate Dehydrogenase 1/2 Mutation in Brainstem Gliomas.

JCO precision oncology·2026
Same author

Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma.

Neuro-oncology·2026
Same author

Representation of neuro-oncology in American neurology departments: An analysis of Grand Rounds and perspectives from faculty and residents.

Neuro-oncology practice·2025
Same author

Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma.

Neuro-oncology·2025

Related Experiment Video

Updated: Feb 13, 2026

Culturing Microglia from the Neonatal and Adult Central Nervous System
11:28

Culturing Microglia from the Neonatal and Adult Central Nervous System

Published on: August 9, 2013

28.9K

Updates on Primary Central Nervous System Lymphoma.

Lauren R Schaff1, Christian Grommes2,3

  • 1Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Current Oncology Reports
|March 2, 2018
PubMed
Summary

Primary central nervous system lymphoma (PCNSL) is a rare brain cancer. Treatment involves methotrexate-based chemotherapy, high-dose chemotherapy, and potentially radiation, with new immunotherapies emerging for relapsed cases.

Keywords:
PCNSLPrimary CNS lymphomaPrimary central nervous system lymphomaTreatment

More Related Videos

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY
10:28

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY

Published on: June 30, 2016

14.1K
Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE
20:51

Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE

Published on: December 4, 2007

16.8K

Related Experiment Videos

Last Updated: Feb 13, 2026

Culturing Microglia from the Neonatal and Adult Central Nervous System
11:28

Culturing Microglia from the Neonatal and Adult Central Nervous System

Published on: August 9, 2013

28.9K
Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY
10:28

Optical Clearing of the Mouse Central Nervous System Using Passive CLARITY

Published on: June 30, 2016

14.1K
Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE
20:51

Isolation of Mononuclear Cells from the Central Nervous System of Rats with EAE

Published on: December 4, 2007

16.8K

Area of Science:

  • Neuro-oncology
  • Hematology
  • Oncology

Background:

  • Primary central nervous system lymphoma (PCNSL) is a rare and aggressive malignancy.
  • Limited randomized trials contribute to varied management approaches in the oncologic community.

Purpose of the Study:

  • To review recent literature on PCNSL.
  • To guide current clinical practice for PCNSL management.

Main Methods:

  • Review of recent literature on PCNSL presentation, workup, and management.
  • Discussion of induction and consolidation therapy strategies.
  • Exploration of treatment for relapsed and refractory disease.

Main Results:

  • Methotrexate-based chemotherapy is a standard induction therapy.
  • High-dose chemotherapy with or without stem cell rescue and whole brain radiation therapy (WBRT) are consolidation options.
  • Immunotherapy and targeted treatments show promise for recurrent/refractory PCNSL.

Conclusions:

  • PCNSL management lacks consensus and requires individualized treatment plans.
  • Consideration of neurotoxicity risk is crucial in treatment decisions.
  • Novel strategies are under development, and clinical trial enrollment is encouraged.